Quotes 5-day view Delayed Nasdaq
1 287 879
2 522 699 Volume
Estimated financial data (e) (USD)
Net income 2022
Net cash position 2022
P/E ratio 2022
1 059 M
Net income 2023
Net cash position 2023
P/E ratio 2023
6 627 M
6 627 M
EV / Sales 2022
EV / Sales 2023
Nbr of Employees
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy...
Ratings of Sarepta Therapeutics, Inc.
All news about SAREPTA THERAPEUTICS, INC.
10:43a Roche, Sarepta Therapeutics' Muscular Disorder Drug Shows Benefit in Clinical Studies
08:15a Sarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystr..
07/05 SAREPTA THERAPEUTICS TO SHARE NEW CL : 30am ET
06/30 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/24 Cantor Fitzgerald Adjusts Sarepta Therapeutics' Price Target to $128 from $140, Keeps O..
06/24 Credit Suisse Lowers Sarepta Therapeutics' Price Target to $90 from $95 After Muscular ..
06/23 Sarepta Therapeutics' Muscular Dystrophy Drug Study Put on FDA Hold; Stock Falls in Lat..
06/23 TRANSCRIPT : Sarepta Therapeutics, Inc. - Special Call
06/23 Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular..
06/23 Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Mu..
06/23 Sarepta Says FDA Put Clinical Hold on Duchenne MD Drug, Shares Fall 8%
06/14 TRANSCRIPT : Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healt..
06/03 SAREPTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matt..
06/02 Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of..
06/02 Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of D..
News in other languages on SAREPTA THERAPEUTICS, INC.
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
JPMorgan moves healthcare conference online amid Omicron concerns
Chart SAREPTA THERAPEUTICS, INC.
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Number of Analysts
Last Close Price
Average target price
Spread / Average Target